| Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. | |
| | |
MedLine Citation:
|
PMID: 15556056 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: To investigate the effect of valsartan in the Valsartan-Heart Failure Trial (Val-HeFT) when added to angiotensin-converting enzyme inhibitor (ACEi) alone in patients with heart failure (HF). METHODS: Subjects in Val-HeFT receiving ACEi but not beta-blocker at baseline were analysed; 1532 were assigned to valsartan and 1502 assigned to placebo. Primary outcome events (all-cause mortality, hospitalisation for adjudicated heart failure, sudden death with resuscitation and need for >4 h of parenteral therapy for worsening heart failure) were monitored. RESULTS: Mortality was not affected by valsartan but morbidity endpoints were significantly reduced (36.3% in placebo, 31.0% in valsartan, p=0.002) in patients receiving an ACEi but no beta-blocker. Quality of life (QOL) was significantly improved, ejection fraction (EF) significantly increased, left ventricular (LV) diameter significantly reduced and plasma B-type natriuretic peptide, norepinephrine and aldosterone levels significantly reduced with valsartan compared to placebo. The morbidity benefit was significant in patients on ACEi doses below the median (22% reduction, p=0.003) and not statistically significant in those receiving ACEi doses above the median (14% reduction, p=0.143). CONCLUSION: Valsartan reduces heart failure hospitalisations and slows LV remodelling in patients treated with an ACEi in the absence of beta-blockade, particularly in those on lower doses of ACEi. |
| | |
Authors:
|
Henry Krum; Peter Carson; Csaba Farsang; Aldo P Maggioni; Robert D Glazer; Nora Aknay; Yann-Tong Chiang; Jay N Cohn |
Related Documents
:
|
2887096 - Interventions that potentially limit myocardial infarct size: overview of clinical trials. 1660796 - Acute effects of the ace inhibitor lisinopril on cardiac electrophysiological parameter... 20419486 - Ivabradine: from molecular basis to clinical effectiveness. 2577296 - Pharmacology of acute effort angina. 10613986 - Monophosphoryl lipid a: a novel agent for inducing pharmacologic myocardial preconditio... 2887096 - Interventions that potentially limit myocardial infarct size: overview of clinical trials. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: European journal of heart failure Volume: 6 ISSN: 1388-9842 ISO Abbreviation: Eur. J. Heart Fail. Publication Date: 2004 Dec |
Date Detail:
|
Created Date: 2004-11-23 Completed Date: 2006-05-16 Revised Date: 2011-06-08 |
Medline Journal Info:
|
Nlm Unique ID: 100887595 Medline TA: Eur J Heart Fail Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 937-45 Citation Subset: IM |
Affiliation:
|
Monash University Medical School, Alfred Hospital, Melbourne, Australia. henry.mrum@med.monash.edu.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angiotensin-Converting Enzyme Inhibitors / administration & dosage, adverse effects, therapeutic use* Antihypertensive Agents / administration & dosage, adverse effects, therapeutic use* Blood Pressure / drug effects Death, Sudden, Cardiac / epidemiology, etiology Dose-Response Relationship, Drug Female Follow-Up Studies Heart Failure / drug therapy*, mortality, physiopathology Heart Rate / drug effects Humans Male Middle Aged Quality of Life Risk Factors Single-Blind Method Stroke Volume / drug effects Survival Analysis Tetrazoles / administration & dosage, adverse effects, therapeutic use* Treatment Outcome Valine / administration & dosage, adverse effects, analogs & derivatives*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Tetrazoles; 137862-53-4/valsartan; 7004-03-7/Valine |
| Comments/Corrections | |
Comment In:
|
Evid Based Cardiovasc Med. 2005 Jun;9(2):115-6
[PMID:
16380005
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in ...
Next Document: Austrian survey of treating heart failure--AUSTRIA.